The Centers for Disease Control and Prevention and Food and Drug Administration are investigating a multistate outbreak of salmonella linked to products reported to contain kratom, a plant consumed for its stimulant effects and as an opioid substitute. According to CDC, 28 people in 20 states have been infected since mid-October, 11 of whom were hospitalized. No common brands or suppliers of kratom have been identified. The agencies are advising consumers to avoid kratom and kratom-containing products. “In addition to the public health concerns raised by this outbreak, kratom affects the same opioid brain receptors as morphine and appears to have properties that expose people who consume kratom to the risks of addiction, abuse and dependence,” FDA said. In other news, FDA today announced the voluntary destruction and recall of kratom-containing dietary supplements made by Divinity Products Distribution. The agency is not aware of recent reports of illness associated with the Divinity products, but asks health care professionals to report any adverse events involving kratom products to its Safety Reporting Portal.
 

Related News Articles

Headline
The Government Accountability Office yesterday released a report calling for the Department of Health and Human Services to improve its efforts responding to…
Headline
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class non-opioid drug, to treat moderate to…
Headline
In this conversation, Vinnidhy Dave, D.O., hospice specialist and director of palliative medicine at Englewood Health Physician Network, and Lauren Savage,…
Headline
In this conversation, Matthew Hoag, director of integrated behavioral health at Denver Health, shares how the organization is innovating through integration to…
Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…